Animal diseases

TNO Study Shows Efficacy of Corona Canon Against Covid-19

Retrieved on:

Friday, June 4, 2021

Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Corona, Biocides, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, COVID-19

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.

Key Points:

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.
Research by TNO1shows that the corona canon reduces the SARS COV-2 virus on stainless steel surfaces by 94.9 percent within fifteen minutes.
In the Netherlands, some schools, hair salons and a funeral home are already working with the corona canon.
That is why we are pleased that TNO has successfully demonstrated the antiviral effect of the Shycocan," says Jongbloed.

TNO Study Shows Efficacy of Corona Canon Against Covid-19

Retrieved on:

Friday, June 4, 2021

Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Corona, Biocides, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, COVID-19

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.

Key Points:

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.
Research by TNO1shows that the corona canon reduces the SARS COV-2 virus on stainless steel surfaces by 94.9 percent within fifteen minutes.
In the Netherlands, some schools, hair salons and a funeral home are already working with the corona canon.
That is why we are pleased that TNO has successfully demonstrated the antiviral effect of the Shycocan," says Jongbloed.

University Products LLC Highlighted the Recent Antibiotic-Treatment Regulation by FDA in Bovine Herds as Critically Necessary; Also Indicated in New Pew Trust Research

Retrieved on:

Wednesday, June 2, 2021

Tick-borne diseases, Rickettsioses, Anaplasmosis, Animal diseases, Medical specialties, Vaccine, Clinical medicine

University Products LLC is the only maker of a successful bovine anaplasmosis vaccine.

Key Points:

University Products LLC is the only maker of a successful bovine anaplasmosis vaccine.
"Dr. Hyun specifically mentions anaplasmosis in this research because of the complexity of the ongoing problem," said Dr. Gene Luther.
The anaplasmosis vaccine developed by Dr. Luther for University Products has been widely deployed in multiple U.S. states and Puerto Rico.
For more information on the vaccine and availability for farmers and producers, have your veterinarian contact Dr. Luther directly by email at [email protected] .

OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses

Retrieved on:

Wednesday, June 2, 2021

Medical specialties, Animal diseases, Clinical medicine, HIV/AIDS, Infectious diseases, Zoonoses, World Health Organization, Immunology, Opportunistic infection, Histoplasmosis, Shingles, Cryptococcosis

OLUMIANT was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.

Key Points:

OLUMIANT was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.
SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death.
Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.
Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with Olumiant.

Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials

Retrieved on:

Tuesday, June 1, 2021

Sarbecovirus, Zoonoses, Medical specialties, Animal diseases, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus 2, Cytopathic effect, Severe acute respiratory syndrome coronavirus, Viral disease

Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.

Key Points:

Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.
In a preclinical experiment using a CPE (cytopathic effect assay), balixafortide demonstrated strong and robust activity against SARS-CoV-2 (COVID-19) infection at clinically relevant concentrations with no adverse cytotoxic effects.
In an in vivo hamster animal model, balixafortide showed positive and statistically significant reduction of viral load of SARS COV-2.
Balixafortide also reduced COVID19-relevant inflammation markers in the lung including ISG15 gene expression, a key player of respiratory failure in viral infections.

Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Thursday, May 27, 2021

Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.

Key Points:

It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.
This webinar will pull back the curtain on partnering with the biopharmaceutical industry for vaccine development as a world class specialty laboratory.
For more information, or to register for this event, visit Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Sixth Wave Partners with ACAMP to Develop RFID Enabled Virus Detection Products Utilizing AMIPs(TM)

Retrieved on:

Tuesday, May 25, 2021

Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Bat virome, Severe acute respiratory syndrome, COVID-19

SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.

Key Points:

SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.
ACAMP facilities have over 14,000 square feet of lab space and house over $15 million in specialized product development equipment.
Offering unparalleled access to world-class engineering expertise, and advanced design, analysis, testing and manufacturing equipment, ACAMP can provide support at every stage of development.
AMIPs is a leading-edge detection platform that uses synthetic polymers to swiftly detect viruses such as the SARS-CoV-2 virus that causes COVID-19.

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

Retrieved on:

Tuesday, May 25, 2021

Biotechnology, Infectious diseases, Health, Science, Research, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Ruo, Severe acute respiratory syndrome

Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research.

Key Points:

Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research.
Waters SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.
Waters developed the SARS-CoV-2 LC-MS Kit (RUO) in support of a coalition of academic, commercial and government research scientists1.
This kit is for research use only and has not been approved for use in clinical diagnostic procedures.

Bites, Camera, Action: Los Angeles Ranks #1 on Orkin's 2021 Mosquito Cities List

Retrieved on:

Monday, May 24, 2021

Flaviviruses, Medical specialties, Veterinary medicine, Animal diseases, Ectoparasites, Viral encephalitis, Mosquito, Insect repellent, Zika fever, West Nile virus, Eastern equine encephalitis, Equine encephalitis

"\nAside from biting humans, the pest is infamous for transmitting West Nile virus, among other diseases such as Eastern Equine Encephalitis and Zika.

Key Points:

"\nAside from biting humans, the pest is infamous for transmitting West Nile virus, among other diseases such as Eastern Equine Encephalitis and Zika.
These dangers apply to both human and pets.\nKnowing what conditions draw mosquitoes can help residents avoid an introduction to them.
By reducing or eliminating those attractants, and wearing insect repellent, you help protect yourself from mosquito bites and the risks associated with them.
Follow us on Facebook , LinkedIn , YouTube and Instagram .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/bites-camera-action-los-angeles-...\n'

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

Retrieved on:

Thursday, May 20, 2021

Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Clinical trials, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, IPA’s PolyTope Platform, ImmunoPrecise Antibodies Ltd., IPA’S POLYTOPE PLATFORM, IMMUNOPRECISE ANTIBODIES LTD.

To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.

Key Points:

To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.
In IPA\xe2\x80\x99s preclinical study:\nIPA\xe2\x80\x99s TATX-03b PolyTope antibody cocktail was administered as a single dose to hamsters that had been infected with SARS-CoV-2 mutant D614G.
TATX-03b is highly efficacious, clearing replication-competent viral titer to undetectable levels in the lung in 100% (five out of five) animals.
\xe2\x80\x9cThese variants will continue to create a moving target for vaccines and therapeutics that were not rationally designed to withstand the emergence of novel variants and strains.